Northside Hospital
Trial Pipeline
Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide
NCT06828796
CAR T-cell Therapy in Patients With Renal Dysfunction
NCT05909059
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
NCT06046248
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
NCT05519579
Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation
NCT05417971
GM-CSF With Post-Transplant Cyclophosphamide
NCT04237623
Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
NCT02828592
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
NCT02581007
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
NCT01244906
Caregiver Burden and Distress in Hematopoeitic Stem Cell Transplant
NCT01084694
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 35 |
What the Pipeline for Northside Hospital Shows
According to the ClinicalTrials.gov registry, Northside Hospital is linked to 37 US clinical trials across every stage of research activity. Of those, 34 studies are currently recruiting — about 92% of the sponsor's indexed portfolio — and 3 are already marked complete, representing roughly 8% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Northside Hospital reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 35 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Northside Hospital is Multiple Myeloma with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.